KR20190135545A - 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제 - Google Patents

고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제 Download PDF

Info

Publication number
KR20190135545A
KR20190135545A KR1020197034945A KR20197034945A KR20190135545A KR 20190135545 A KR20190135545 A KR 20190135545A KR 1020197034945 A KR1020197034945 A KR 1020197034945A KR 20197034945 A KR20197034945 A KR 20197034945A KR 20190135545 A KR20190135545 A KR 20190135545A
Authority
KR
South Korea
Prior art keywords
alkyl
substituted
unsubstituted
group
carbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197034945A
Other languages
English (en)
Korean (ko)
Inventor
브로니슬라바 제두린
마이클 그레이
니얼 오도넬
Original Assignee
루메나 파마수티컬즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 루메나 파마수티컬즈, 인코포레이티드 filed Critical 루메나 파마수티컬즈, 인코포레이티드
Priority to KR1020217033783A priority Critical patent/KR20210131431A/ko
Publication of KR20190135545A publication Critical patent/KR20190135545A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
KR1020197034945A 2011-10-28 2012-10-26 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제 Ceased KR20190135545A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217033783A KR20210131431A (ko) 2011-10-28 2012-10-26 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161553094P 2011-10-28 2011-10-28
US61/553,094 2011-10-28
US201261607487P 2012-03-06 2012-03-06
US61/607,487 2012-03-06
PCT/US2012/062303 WO2013063526A1 (en) 2011-10-28 2012-10-26 Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147014267A Division KR102051031B1 (ko) 2011-10-28 2012-10-26 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217033783A Division KR20210131431A (ko) 2011-10-28 2012-10-26 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제

Publications (1)

Publication Number Publication Date
KR20190135545A true KR20190135545A (ko) 2019-12-06

Family

ID=48168615

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197034945A Ceased KR20190135545A (ko) 2011-10-28 2012-10-26 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
KR1020217033783A Ceased KR20210131431A (ko) 2011-10-28 2012-10-26 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
KR1020147014267A Active KR102051031B1 (ko) 2011-10-28 2012-10-26 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217033783A Ceased KR20210131431A (ko) 2011-10-28 2012-10-26 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
KR1020147014267A Active KR102051031B1 (ko) 2011-10-28 2012-10-26 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제

Country Status (15)

Country Link
US (6) US20130108573A1 (https=)
EP (2) EP3278796A1 (https=)
JP (4) JP6217939B2 (https=)
KR (3) KR20190135545A (https=)
CN (2) CN104023718B (https=)
AU (3) AU2012328453B2 (https=)
BR (1) BR112014010228B1 (https=)
CA (1) CA2852957C (https=)
EA (2) EA038594B1 (https=)
HK (1) HK1249045A1 (https=)
IL (2) IL232149A0 (https=)
MX (2) MX382960B (https=)
SG (3) SG11201401816SA (https=)
WO (1) WO2013063526A1 (https=)
ZA (1) ZA201403367B (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687027T3 (es) 2010-11-04 2018-10-23 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepáticas
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
AU2012328526B2 (en) * 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
CA2907230A1 (en) * 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
WO2015065983A1 (en) * 2013-10-29 2015-05-07 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of gastrointestinal infections
JP2017515854A (ja) 2014-05-12 2017-06-15 クオナトウス ファーマシューティカルズ，インコーポレイテッド カスパーゼ阻害剤による慢性肝疾患の合併症の治療
EA036342B1 (ru) 2014-06-13 2020-10-29 Инвентива Применение панагониста ppar, а именно 5-хлор-1-[(6-бензотиазолил)сульфонил]-1н-индол-2-бутановой кислоты, для лечения фибротических состояний
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
HUE050317T2 (hu) 2015-05-20 2020-11-30 Amgen Inc APJ receptor triazol agonistái
CA3010286A1 (en) 2015-12-31 2017-07-06 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
WO2017138878A1 (en) 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
CN108601739B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 考来烯胺丸剂及其制备方法
ES2874669T3 (es) 2016-02-09 2021-11-05 Albireo Ab Formulación oral de colestiramina y uso de la misma
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
CN108990420B (zh) 2016-05-29 2022-06-24 深圳市绘云生物科技有限公司 肝病相关生物标志物和其使用方法
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
WO2018093576A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
EP3746091A4 (en) * 2018-01-30 2021-10-06 Pharmascience Inc. CHOLESTYRAMINE FORMULATIONS AND METHODS OF USE
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
PL3810581T3 (pl) * 2018-06-20 2025-04-28 Albireo Ab Modyfikacje kryształu odewiksibatu
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
TWI835997B (zh) 2019-02-06 2024-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其用作膽酸調節劑之用途
CN118852054A (zh) 2019-02-06 2024-10-29 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
EP3923943B1 (en) 2019-02-12 2024-07-31 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
WO2020194531A1 (ja) * 2019-03-26 2020-10-01 国立大学法人東北大学 血中尿毒症物質の低減剤
JP7696898B2 (ja) 2019-12-04 2025-06-23 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
IL293379B2 (en) 2019-12-04 2026-04-01 Albireo Ab Benzothia(dia)azepine compounds and their use as bile acid modulators
ES2973355T3 (es) 2019-12-04 2024-06-19 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
EP4069247B1 (en) 2019-12-04 2025-03-26 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
EP4188541B1 (en) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CN116710100A (zh) * 2020-11-12 2023-09-05 阿尔比里奥公司 用于治疗进行性家族性肝内胆汁淤积(pfic)的奥德昔巴特
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
TW202333723A (zh) * 2021-10-26 2023-09-01 美商米魯姆製藥公司 頂端鈉依賴型膽酸轉運蛋白抑制劑(asbti)之給藥方法
TW202333724A (zh) * 2021-11-05 2023-09-01 美商米魯姆製藥公司 以迴腸膽酸轉運蛋白(ibat)抑制劑治療以增加無事件存活期(efs)
JP2023160476A (ja) * 2022-04-22 2023-11-02 株式会社三共 遊技機
KR20250093383A (ko) * 2022-10-23 2025-06-24 미룸 파마슈티컬스, 인크. 진행성 가족성 간내 담즙정체를 치료하는 방법
WO2024121431A1 (en) * 2022-12-09 2024-06-13 Albireo Ab Cocrystals of odevixibat

Family Cites Families (275)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE580490A (fr) 1958-07-15 1960-01-08 Merck & Co Inc Compositions et procédés pour abaisser la teneur en cholestérol du sang
US3308020A (en) 1961-09-22 1967-03-07 Merck & Co Inc Compositions and method for binding bile acids in vivo including hypocholesteremics
US3383281A (en) 1961-09-22 1968-05-14 Merck & Co Inc Method for binding bile acids in vivo
US3287370A (en) 1965-06-08 1966-11-22 Mcneilab Inc Tetrahydrobenzothiepins
US3389144A (en) 1965-06-08 1968-06-18 Mcneilab Inc 5-pyridyl-2, 3, 4, 5-tetrahydrobenzothiepin-5-ols
DE1593760A1 (de) 1967-02-01 1972-06-08 Boehringer Sohn Ingelheim Verfahren zur Herstellung neuer Benz-epinderivate
US3444176A (en) 1967-04-28 1969-05-13 Mcneilab Inc Certain 4-diloweralkylamino-lower alkyl - 5 - pyridyl (or phenyl)-2,3-dihydro - 1 - benzothiepins and derivatives thereof
GB1269551A (en) 1969-03-27 1972-04-06 Science Union & Cie New tricyclic derivatives and process for their manufacture
NL7017227A (https=) 1969-12-27 1971-06-29
US3694446A (en) 1970-02-24 1972-09-26 William J Houlihan 5-(substituted-benzyl)-benzocycloheptenes and-1-benzthiepines
CH537404A (de) 1970-09-24 1973-05-31 Sandoz Ag Verfahren zur Herstellung neuer Thiophenderivate
CH531000A (de) 1970-03-11 1972-11-30 Sandoz Ag Verfahren zur Herstellung neuer Benzocycloheptathiophene
US3758528A (en) 1970-03-13 1973-09-11 Science Union & Cie Tricyclic compounds
US3821249A (en) 1970-03-13 1974-06-28 En Nom Collectif Science Union Dibenzothiazefin derivatives
GB1348642A (en) 1970-10-15 1974-03-20 Howard A N Hypocholesterolaemic compositions
US3769399A (en) 1971-03-05 1973-10-30 L Hagerman Intestinal bile acid binding process and compositions
JPS4711953U (https=) 1971-03-08 1972-10-12
GB1428110A (en) 1972-05-30 1976-03-17 Reckitt & Colmann Prod Ltd Pharmaceutical antihypertensive and vasodilator compositions
US3974272A (en) 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
CH582699A5 (https=) 1973-03-26 1976-12-15 Sandoz Ag
CH593970A5 (en) 1973-03-30 1977-12-30 Hoffmann La Roche 10-(4-Substd. piperazino) dibenzo (b,f) thiepins - CNS depressants without cataleptic side-effects
US3954764A (en) 1973-03-30 1976-05-04 Hoffmann-La Roche Inc. Dibenzo [b,f]thiepins bearing piperazinyl substitution
US4044010A (en) 1973-03-30 1977-08-23 Hoffmann-La Roche Inc. Dibenzo[b,f] thiepins bearing piperazinyl substitution
US3928383A (en) 1973-06-08 1975-12-23 Hoffmann La Roche Propynylamine-substituted dibenzo{8 b,f{9 thiepins and dibenz{8 b,f{9 oxepins
SE7504508L (sv) 1974-05-10 1975-11-11 Ciba Geigy Ag Nya heterocykliska s-imino-s-oxider.
SE420725B (sv) 1974-09-26 1981-10-26 Ciba Geigy Ag Sett att framstella 2,3-dihydro-1-benstiepin-4-karboxylsyraamider
US4252790A (en) 1974-10-23 1981-02-24 Interx Research Corporation Method for treating gastric ulcer-prone patients
GB1566609A (en) 1977-03-10 1980-05-08 Reckitt & Colmann Prod Ltd Pharmaceutical compositions containing cholestyramine and alginic acid
US4207239A (en) 1977-10-31 1980-06-10 The Upjohn Company Benzothiepins
US4153612A (en) 1977-10-31 1979-05-08 The Upjohn Company 2-Benzoxepins
US4251526A (en) 1977-10-31 1981-02-17 Mccall John M 2-Benzothiepins and compositions and methods of use therefore
US4247533A (en) 1978-05-01 1981-01-27 The Rockefeller University Hemoglobin A1c radioimmunoassay
IT1106718B (it) 1978-12-21 1985-11-18 Alfa Farmaceutici Spa Composizioni a base di resine anioniche salificate farmacologicamente attive
US5169857A (en) 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
AU548253B2 (en) 1981-05-11 1985-12-05 Pierre Fabre S.A. Benzoxepine derivatives and sulphur and nitrogen analogues thereof
US4647459A (en) 1983-07-20 1987-03-03 Warner-Lambert Company Confectionery compositions containing magnesium trisilicate adsorbates
NO170760C (no) 1985-01-10 1992-12-02 Tanabe Seiyaku Co Analogifremgangsmaate for fremstilling av terapeutisk aktive nafthalenderivater
AU597671B2 (en) 1986-06-20 1990-06-07 Suntory Limited 2-Phenylbenzoxepin derivative
JPS6310746A (ja) 1986-07-01 1988-01-18 Tanabe Seiyaku Co Ltd ナフタレン誘導体
US4895723A (en) 1986-09-08 1990-01-23 Amer And Company Cholestyramine compositions and method for preparation thereof
US4814354A (en) 1986-09-26 1989-03-21 Warner-Lambert Company Lipid regulating agents
ZA876930B (en) 1986-10-07 1988-05-25 Hoffmann La Roche Pharmaceutical compositions
AU626881B2 (en) 1988-07-14 1992-08-13 F. Hoffmann-La Roche Ag Benzofused heterocyclics used as pharmaceuticals
US5164387A (en) 1988-07-14 1992-11-17 Hoffmann-Laroche Inc. Condensed heterocyclic compounds
US5158943A (en) 1988-11-21 1992-10-27 Takeda Chemical Industries, Ltd. Sulfur-containing heterocyclic compounds
US4874744A (en) 1989-03-13 1989-10-17 University Of Cincinnati Method of using melanocyte stimulating hormone as dermatis treatment
US5275823A (en) 1989-04-27 1994-01-04 Smith Kline & French Laboratories Ltd. Pharmaceutical compositions
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US4997665A (en) 1989-10-05 1991-03-05 Michigan Biotechnology Institute Dietary fibers and a process for their production
FR2661676A1 (fr) 1990-05-02 1991-11-08 Lipha Derives d'amino benzocycloalcanes, procedes de preparation et medicaments les contenant.
US5250524A (en) 1990-12-06 1993-10-05 Hoechst Aktiengesellschaft Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals
IT1245890B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
EP0583346A1 (en) 1991-04-12 1994-02-23 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
JP2839805B2 (ja) 1991-10-17 1998-12-16 塩野義製薬株式会社 リグナン類縁体及びその製造方法ならびに抗高脂血症剤
EP0549967B1 (de) 1991-12-20 1996-03-13 Hoechst Aktiengesellschaft Polymere und Oligomere von Gallensäurederivaten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
DK0573848T3 (da) 1992-06-12 1998-08-10 Hoechst Ag Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
US5415872A (en) 1992-06-22 1995-05-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
FR2698873B1 (fr) 1992-12-07 1995-02-24 Lipha Benzocycloheptènes, benzoxépines et benzothiépines activateurs des canaux potassiques, procédé de préparation, composition pharmaceutique les contenant.
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
US5594001A (en) 1993-04-08 1997-01-14 The Dupont Merck Pharmaceutical Company Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders
DE69411243T2 (de) 1993-04-16 1998-11-19 Shionogi & Co Verfahren zur herstellung eines lignan-derivats
DE4314583A1 (de) 1993-04-29 1994-11-03 Astra Chem Gmbh Colestyramin enthaltende Zusammensetzung und Verfahren zu deren Herstellung
EP0624593A3 (de) 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
TW289020B (https=) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
TW289021B (https=) 1993-05-08 1996-10-21 Hoechst Ag
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
DE59407041D1 (de) 1993-08-30 1998-11-12 Medichemie Ag Ursodeoxycholsäure enthaltendes Arzneimittel in flüssiger Darreichungsform
US5589358A (en) 1993-12-29 1996-12-31 Univ Wake Forest Ileal bile acid transporter compositions and methods
US5491152A (en) 1994-03-23 1996-02-13 The Du Pont Merck Pharmaceutical Company Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
KR970005178Y1 (ko) 1994-07-06 1997-05-24 김상수 개량형 노통연관 보일러
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6107494A (en) 1994-09-13 2000-08-22 G.D. Searle And Company Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US5994391A (en) 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
CN1084741C (zh) 1994-09-13 2002-05-15 孟山都公司 具有回肠胆汁酸转运和牛磺胆酸盐摄入抑制剂作用的新的苯并硫杂䓬
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US6034118A (en) 1994-11-04 2000-03-07 Gilead Sciences, Inc. Thiepane compounds
GB9423172D0 (en) 1994-11-17 1995-01-04 Wellcom Foundation The Limited Hypolipidemic benzothiazepines
US5721103A (en) 1994-12-30 1998-02-24 Ligand Pharmaceuticals Incorporated Trienoic retinoid compounds and methods
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5886016A (en) 1995-09-15 1999-03-23 G.D. Searle & Co. Benzopyranopyrazolyl derivatives for the treatment of inflammation
AU720853B2 (en) 1995-11-02 2000-06-15 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration
AU724620B2 (en) 1996-01-16 2000-09-28 Sokol, Ronald J Dr. Use of antioxidant agents to treat cholestatic liver disease
GB9601697D0 (en) 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
HUP9903047A3 (en) 1996-03-11 2002-12-28 G D Searle & Co Chicago Novel benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
EP0929575A4 (en) 1996-08-23 2004-09-08 Human Genome Sciences Inc NEW HUMAN GROWTH FACTORS.
JPH1072371A (ja) 1996-08-28 1998-03-17 Sankyo Co Ltd 回腸型胆汁酸トランスポーター阻害剤
US6251852B1 (en) 1996-09-18 2001-06-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
GB9704208D0 (en) 1997-02-28 1997-04-16 Glaxo Group Ltd Chemical compounds
PL336415A1 (en) 1997-03-11 2000-06-19 Searle & Co Combined therapy employing ileic bile acid transport inhibiting benzothiepins as well as a hmg co-enzyme reductase inhibitors
DK0864582T3 (da) 1997-03-14 2003-09-29 Aventis Pharma Gmbh Hypolidemiske 1,4-benzothiazepin-1,1-dioxider
EP0869121B1 (de) 1997-04-04 2004-06-09 Aventis Pharma Deutschland GmbH Hypolipidämische Propanolaminderivate
DE19845402B4 (de) 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
IT1292092B1 (it) 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
AU7552198A (en) 1997-06-11 1998-12-30 Sankyo Company Limited Benzylamine derivatives
GB9714274D0 (en) 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
US6180660B1 (en) 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
US6066336A (en) 1997-09-29 2000-05-23 Bristol-Myers Squibb Company Cholesterol-lowering tablets
US5900233A (en) 1997-10-16 1999-05-04 Day; Charles E. Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome
US6245797B1 (en) 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
DE19755480A1 (de) 1997-12-13 1999-06-24 Gruenenthal Gmbh Substituierte heterocyclische Benzocycloalkene und ihre Verwendung als analgetisch wirksame Substanzen
ATE234829T1 (de) 1997-12-19 2003-04-15 Searle & Co Verfahren zu herstellung von enantiomerisch- anreicherte tetrahydrobenzothiepin oxyden
GB9800428D0 (en) 1998-01-10 1998-03-04 Glaxo Group Ltd Chemical compounds
EP2583675A1 (en) 1998-02-02 2013-04-24 Trustees Of Tufts College Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (de) 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JP2000026300A (ja) 1998-07-02 2000-01-25 Pola Chem Ind Inc 血管内皮細胞保護医薬組成物
EP1103552A4 (en) 1998-08-07 2003-01-15 Takeda Chemical Industries Ltd BENZOTHIEPINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE
AU5301599A (en) 1998-08-20 2000-03-14 Takeda Chemical Industries Ltd. Quaternary ammonium salts and their use
DE19845403B4 (de) 1998-10-02 2005-02-10 Aventis Pharma Deutschland Gmbh Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845406C2 (de) 1998-10-02 2001-10-18 Aventis Pharma Gmbh Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
AU1684400A (en) 1998-12-11 2000-07-03 Sankyo Company Limited Substituted benzylamines
AU1690100A (en) 1998-12-21 2000-07-12 Takeda Chemical Industries Ltd. Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5
WO2000038727A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
PT1140190E (pt) 1998-12-23 2003-02-28 Searle Llc Combinacoes de inibidores do transporte ileal dos acidos biliares e agentes sequestrantes dos acidos biliares usadas para problemas cardiovasculares
JP2002533412A (ja) * 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびコレステリルエステル転送タンパク質阻害剤の組み合わせ
KR20020002367A (ko) 1998-12-23 2002-01-09 윌리암스 로저 에이 심혈관 징후를 위한 조합물
JP2002536440A (ja) 1999-02-12 2002-10-29 ジー．ディー．サール エルエルシー 回腸胆汁酸輸送およびタウロコール酸塩取り込みの阻害剤としての活性を有する新規１，２−ベンゾチアゼピン
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
SE9901387D0 (sv) * 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
CZ290178B6 (cs) 1999-07-22 2002-06-12 Sankyo Company Limited Deriváty cyklobutenu
US7413536B1 (en) 1999-09-14 2008-08-19 Xenoport, Inc. Substrates and screening methods for transport proteins
AU1302301A (en) 1999-11-08 2001-06-06 Sankyo Company Limited Nitrogenous heterocycle derivatives
AU3104301A (en) * 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
EP1743655B1 (en) 2000-01-21 2014-06-25 Novartis AG Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
WO2001068096A2 (en) 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US6586434B2 (en) 2000-03-10 2003-07-01 G.D. Searle, Llc Method for the preparation of tetrahydrobenzothiepines
CA2401290A1 (en) 2000-04-12 2001-10-18 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
RU2241462C2 (ru) 2000-07-28 2004-12-10 Ф. Хоффманн-Ля Рош Аг Новая фармацевтическая композиция
SE0003766D0 (sv) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
US7198914B2 (en) 2000-11-17 2007-04-03 Banyu Pharmaceutical Co., Ltd. Guanosine triphosphate (GTP)-binding protein-coupled receptor protein, BG37
EP1345895B1 (de) 2000-12-21 2006-12-27 Sanofi-Aventis Deutschland GmbH Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
PL364178A1 (en) 2001-01-26 2004-12-13 Schering Corporation Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
AU2002306868A1 (en) 2001-03-28 2002-10-15 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
US20030149010A1 (en) 2001-07-19 2003-08-07 Keller Bradley T. Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor
RS11104A (sr) 2001-08-22 2006-12-15 Sanofi Aventis Deutschland Gmbh. Kombinovani preparati derivata 1,4-benzotiepin-1,1-dioksida sa drugim aktivnim supstancama i njihova primena
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
AU2002329387B2 (en) 2001-09-08 2007-06-07 Albireo Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia
EP1432721A4 (en) 2001-09-13 2008-02-20 Bristol Myers Squibb Co PROCESS FOR THE PREPARATION OF REBECCAMYCIN AND ANALOGUE THEREOF
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
CA2776391C (en) 2001-10-01 2015-03-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
BR0213501A (pt) 2001-11-02 2004-08-24 Searle Llc Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
US6852753B2 (en) 2002-01-17 2005-02-08 Pharmacia Corporation Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
GB0201850D0 (en) 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
US20040014806A1 (en) 2002-03-08 2004-01-22 Pharmacia Corporation Methods and compositions for lowering levels of blood lipids
US6987121B2 (en) * 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
MXPA04011584A (es) 2002-05-23 2005-03-31 Umd Inc Composiciones y metodo para la administracion y crioproteccion de drogas transmucosales.
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
GB0216321D0 (en) 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
CN100494185C (zh) * 2002-08-28 2009-06-03 旭化成制药株式会社 新型季铵化合物
US7312208B2 (en) * 2002-08-28 2007-12-25 Asahi Kasei Pharma Corporation Quaternary ammonium compounds
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US20040122033A1 (en) 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US20040138145A1 (en) 2002-12-12 2004-07-15 Aventis Pharma S.A. Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
US20040147774A1 (en) 2002-12-20 2004-07-29 Aventis Pharma S.A. Novel chiral compounds derived from hexanoic acid esters, preparation process and intermediates, use in the synthesis of chiral 2-(bromomethyl)-2-ethylhexanoic acid
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
JP2005044778A (ja) 2003-07-19 2005-02-17 Samsung Sdi Co Ltd 電界発光素子
JP2005097216A (ja) 2003-09-26 2005-04-14 Kaneka Corp ＰＰＡＲγリガンド剤
EP1680189A2 (en) 2003-11-05 2006-07-19 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
EP1564554A1 (en) 2004-02-12 2005-08-17 Pepscan Systems B.V. Method for the detection of early B cell populations in vaccine development
KR20070026392A (ko) 2004-02-27 2007-03-08 아사히 가세이 파마 가부시키가이샤 신규 벤조티아제핀 및 벤조티에핀 화합물
DE102004016845A1 (de) 2004-04-07 2005-10-27 Bayer Healthcare Ag Phenylthioessigsäure-Derivate und ihre Verwendung
WO2006017257A2 (en) 2004-07-12 2006-02-16 Phenomix Corporation Azetidinone derivatives
EP1799263A4 (en) 2004-09-15 2009-07-29 Harvard College REDUCTION OF ER-STRESS IN THE TREATMENT OF ADIPOSITAS AND DIABETES
DE102004046623A1 (de) 2004-09-25 2006-03-30 Bayer Healthcare Ag Neue Pyrimidin-Derivate und ihre Verwendung
EP1807070A1 (en) 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
WO2006041150A1 (ja) 2004-10-15 2006-04-20 Mitsubishi Pharma Corporation 糖尿病の予防および／または治療薬
AU2005299808B2 (en) 2004-10-25 2009-08-20 Novartis Ag Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin
EP1819318A1 (en) 2004-11-24 2007-08-22 Seo Hong Yoo Dried forms of aqueous solubilized bile acid dosage formulation
DE102004058062A1 (de) 2004-12-02 2006-06-08 Bayer Healthcare Ag Cyclische Iminocarbamate und ihre Verwendung
CN102633730A (zh) 2004-12-03 2012-08-15 先灵公司 作为cb1拮抗剂的取代哌嗪
WO2006086727A2 (en) 2005-02-09 2006-08-17 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
US20060193895A1 (en) 2005-02-25 2006-08-31 Use-Techno Corporation Additive for food and beverage, pharmaceutical composition, GLUT4 translocator, and method for translocating GLUT4
DE102005027150A1 (de) 2005-03-12 2006-09-28 Bayer Healthcare Ag Pyrimidincarbonsäure-Derivate und ihre Verwendung
FR2883284A1 (fr) 2005-03-15 2006-09-22 Commissariat Energie Atomique Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
UY29445A1 (es) 2005-03-30 2006-10-02 Generex Pharm Inc Composiciones para la transmisión transmucosa oral de la metformina
US20080031968A1 (en) 2005-04-01 2008-02-07 The Brigham And Women's Hospital, Inc. Methods for increasing cellular energy expenditure
WO2006105912A2 (en) 2005-04-04 2006-10-12 Julius-Maximilians-Universität Würzburg Peptides that down regulate the activity of plasma membrane transporters including sodium-d-glucose cotransporter sglt1
AU2006231071B2 (en) 2005-04-04 2012-09-06 Julius-Maximilians-Universitaet Wuerzburg Tripeptides that down regulate the activity of plasma membrane transporters including sodium-D-glucose cotransporter SGLT1
US20080194494A1 (en) 2005-04-26 2008-08-14 Microbia, Inc. 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia
DE102005020229A1 (de) 2005-04-30 2006-11-09 Bayer Healthcare Ag Verwendung von Indolin-Phenylsulfonamid-Derivaten
WO2006116814A1 (en) 2005-05-02 2006-11-09 Vanadis Bioscience Ltd Composition and uses thereof
US20090131395A1 (en) 2005-05-05 2009-05-21 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
WO2006122186A2 (en) 2005-05-10 2006-11-16 Microbia, Inc. 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
TW200740752A (en) 2005-05-13 2007-11-01 Microbia Inc 4-Biarylyl-1-phenylazetidin-2-ones
JP2008542380A (ja) * 2005-05-31 2008-11-27 ノバルティス アクチエンゲゼルシャフト 鉄が病因に関与する肝臓疾患の処置
DE102005033099A1 (de) 2005-07-15 2007-01-18 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung
US20070025953A1 (en) 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
WO2007035703A1 (en) 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist
CA2623826A1 (en) 2005-09-30 2007-04-12 Novartis Ag Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection
WO2007050628A2 (en) 2005-10-24 2007-05-03 Andrew Young Biliary/pancreatic shunt device and method for treatment of metabolic and other diseases
JP5081161B2 (ja) 2005-12-19 2012-11-21 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
AU2006331770A1 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
EP1987000A2 (en) 2006-01-13 2008-11-05 Schering Corporation Diaryl piperidines as cb1 modulators
JP2009528266A (ja) 2006-01-18 2009-08-06 シェーリング コーポレイション カンナビノイド受容体修飾因子
CN101404987A (zh) 2006-01-20 2009-04-08 史密丝克莱恩比彻姆公司 磺酰胺衍生物在治疗代射和神经系统疾病中的用途
JP2010517931A (ja) 2006-02-14 2010-05-27 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒ媒介性の疾患または状態の予防または治療用のｆｘｒリガンドとしての胆汁酸誘導体
DE102006009813A1 (de) 2006-03-01 2007-09-06 Bayer Healthcare Ag Verwendung von A2b/A1 Rezeptor Agonisten zur Modulation der Lipidspiegel
WO2007123949A2 (en) 2006-04-21 2007-11-01 Schering Corporation Cannabinoid receptor modulators
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
DE102006026583A1 (de) 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
DE102006026585A1 (de) 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Substituierte 4-Aryl-1,4-dihydro-1,6-naphthyridine und ihre Verwendung
PT2040713E (pt) 2006-06-27 2014-10-13 Intercept Pharmaceuticals Inc Para a prevenção ou o tratamento de doenças ou estados clínicos mediados por fxr
US20080065136A1 (en) 2006-08-30 2008-03-13 Andrew Young Distender device and method for treatment of obesity and metabolic and other diseases
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006043519A1 (de) 2006-09-12 2008-03-27 Bayer Healthcare Ag 4-Phenoxynikotinsäure-Derivate und ihre Verwendung
DE102006043520A1 (de) 2006-09-12 2008-03-27 Bayer Healthcare Ag 2-Phenoxynikotinsäure-Derivate und ihre Verwendung
CN101541805A (zh) 2006-09-15 2009-09-23 先灵公司 用于治疗疼痛和脂代射紊乱的氮杂环丁烷和氮杂环丁酮衍生物
CA2663500A1 (en) 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
CA2663502A1 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
US20080070890A1 (en) 2006-09-15 2008-03-20 Burnett Duane A Spirocyclic Azetidinone Compounds and Methods of Use Thereof
CA2663503A1 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
US20080070984A1 (en) 2006-09-15 2008-03-20 Tran Pierre V Compositions and Methods of Treating Schizophrenia
WO2008033447A1 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
MX2009002920A (es) 2006-09-15 2009-04-01 Schering Corp Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos.
DE102006044696A1 (de) 2006-09-22 2008-03-27 Bayer Healthcare Ag 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung
WO2008039829A2 (en) 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
WO2008052044A2 (en) 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
DE102006053635B4 (de) 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE502007006208D1 (de) 2006-11-14 2011-02-17 Sanofi Aventis Deutschland Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102006053637B4 (de) * 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
DE102006056739A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
WO2008088836A2 (en) 2007-01-16 2008-07-24 The Burnham Institute For Medical Research Compositions and methods for treatment of colorectal cancer
AU2008209566C1 (en) 2007-01-19 2013-02-14 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as TGR5 modulators and methods of use thereof
US20080221161A1 (en) 2007-02-09 2008-09-11 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
US20100144864A1 (en) 2007-04-05 2010-06-10 Ironwood Pharmaceuticals, Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
WO2008130616A2 (en) 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
NZ583369A (en) 2007-08-23 2011-08-26 Theracos Inc Benzylbenzene derivatives and methods of use
WO2009115398A1 (en) * 2008-03-18 2009-09-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Vitamin d compounds for the treatment of biliary diseases
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
EA020310B1 (ru) 2008-07-30 2014-10-30 Интерсепт Фармасьютикалз, Инк. Модуляторы рецептора tgr5 и их применение
ES2663948T3 (es) 2008-11-19 2018-04-17 Intercept Pharmaceuticals, Inc. Moduladores de TGR5 y método de uso de los mismos
CA2744697C (en) 2008-11-26 2016-06-21 Satiogen Pharmaceuticals, Inc. Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes
WO2010062861A2 (en) * 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
US20110065676A1 (en) 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists
EP2470553B1 (en) 2009-08-25 2024-06-19 Qing Bile Therapeutics Inc. Polyhydroxylated bile acids for treatment of biliary disorders
WO2011075539A2 (en) * 2009-12-18 2011-06-23 Satiogen Pharmaceuticals, Inc. Treatment of obesity or diabetes with bile acid sequestrants
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
ES2687027T3 (es) 2010-11-04 2018-10-23 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepáticas
US20120114588A1 (en) 2010-11-08 2012-05-10 Albireo Ab Ibat inhibitors for treatment of metabolic disorders and related conditions
WO2012064268A1 (en) 2010-11-08 2012-05-18 Albireo Ab Ibat inhibitors for treatment of metabolic disorders and related conditions
DK2637646T3 (en) 2010-11-08 2016-08-29 Albireo Ab PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder
AU2012328526B2 (en) * 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US20130108573A1 (en) * 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
US9007272B2 (en) 2012-07-19 2015-04-14 Tensorcom, Inc. Method and apparatus for the alignment of a 60 GHz endfire antenna
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
SMT202500241T1 (it) 2016-03-31 2025-07-22 Genfit Elafibranor per uso nel trattamento di colangite biliare primitiva
JP7266531B2 (ja) 2017-04-18 2023-04-28 ジェンフィ エラフィブラノール又はその誘導体と抗ｎａｓｈ剤、抗線維化剤又は抗胆汁うっ滞性剤の組合せ

Also Published As

Publication number Publication date
CA2852957C (en) 2020-08-04
US20230212211A1 (en) 2023-07-06
BR112014010228A8 (pt) 2017-06-20
US20250282808A1 (en) 2025-09-11
SG10201903512SA (en) 2019-05-30
CN104023718B (zh) 2017-04-05
KR20210131431A (ko) 2021-11-02
KR102051031B1 (ko) 2019-12-02
MX2019002774A (es) 2019-05-09
AU2019226227A1 (en) 2019-09-26
MX2014005122A (es) 2015-02-12
BR112014010228A2 (pt) 2017-06-13
IL266001A (en) 2019-06-30
JP2019142892A (ja) 2019-08-29
JP2014532663A (ja) 2014-12-08
US20190169217A1 (en) 2019-06-06
WO2013063526A1 (en) 2013-05-02
KR20140084304A (ko) 2014-07-04
MX363161B (es) 2019-03-13
HK1249045A1 (en) 2018-10-26
AU2019226227B2 (en) 2021-08-12
ZA201403367B (en) 2021-05-26
MX382960B (es) 2025-03-13
AU2017210623B2 (en) 2019-06-06
EA201490852A1 (ru) 2014-11-28
CN104023718A (zh) 2014-09-03
EP2770990A4 (en) 2015-03-11
JP2022070878A (ja) 2022-05-13
EA201792541A3 (ru) 2019-03-29
SG10201406155QA (en) 2014-11-27
EP3278796A1 (en) 2018-02-07
CN107375291A (zh) 2017-11-24
IL232149A0 (en) 2014-05-28
EA029581B1 (ru) 2018-04-30
EA201792541A2 (ru) 2018-07-31
IL266001B (en) 2020-11-30
JP2018030855A (ja) 2018-03-01
US20130108573A1 (en) 2013-05-02
US20140323412A1 (en) 2014-10-30
AU2012328453A1 (en) 2014-05-29
CA2852957A1 (en) 2013-05-02
JP6217939B2 (ja) 2017-10-25
EA038594B1 (ru) 2021-09-21
AU2017210623A1 (en) 2017-08-24
EP2770990A1 (en) 2014-09-03
US20200207797A1 (en) 2020-07-02
BR112014010228B1 (pt) 2020-09-29
AU2012328453B2 (en) 2017-05-04
SG11201401816SA (en) 2014-05-29
US12145959B2 (en) 2024-11-19

Similar Documents

Publication Publication Date Title
KR102051031B1 (ko) 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
KR102051030B1 (ko) 소아 담즙울체성 간 질환 치료용 담즙산 재순환 억제제
KR20230152818A (ko) 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
KR20160003664A (ko) 바렛 식도 및 위식도 역류 질환 치료용 담즙산 재순환 억제제

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191126

Application number text: 1020147014267

Filing date: 20140527

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191226

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200317

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201127

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200317

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20201127

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200625

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20191226

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210217

Patent event code: PE09021S01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20210317

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20210720

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210217

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210114

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20201127

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200625

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20200317

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20191226

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20211019

Application number text: 1020147014267

Filing date: 20140527